Erschienen in:
01.08.2011 | Original Article
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
verfasst von:
Yu Sunakawa, Wataru Ichikawa, Ken-ichi Fujita, Fumio Nagashima, Hiroo Ishida, Keishi Yamashita, Keiko Mizuno, Keisuke Miwa, Kaori Kawara, Yuko Akiyama, Kazuhiro Araki, Wataru Yamamoto, Toshimichi Miya, Masaru Narabayashi, Yuichi Ando, Takashi Hirose, Shigehira Saji, Yasutsuna Sasaki
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 2/2011
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Differences in efficacy and toxicity between UDP-glucuronosyltransferase (UGT) 1A1*1/*1 and *1/*6 or *1/*28 genotypes remain unclear in Japanese patients.
Methods
Patients with advanced colorectal cancer who received irinotecan combined with 5-fluorouracil plus l-leucovorin (FOLFIRI) as first-line therapy were divided into two groups: those with UGT1A1*1/*1 genotype and those with UGT1A1*1/*6 or *1/*28 genotype. Efficacy and toxicity were compared between these groups retrospectively.
Results
Forty-two patients (24 *1/*1 and 18 *1/*6 or *1/*28) were evaluated. The response rate was 48% in *1/*1 group and 56% in *1/*6 or *1/*28 group (P = 0.847). Median progression-free survival was 8.6 months in *1/*1 group and 8.5 months in *1/*6 or *1/*28 group (P = 0.888). No hematologic or non-hematologic toxic effects were clearly related to UGT1A1*1/*6 or *1/*28 during the first cycle or throughout the entire course of chemotherapy.
Conclusions
There were no significant differences in the efficacy or toxicity of FOLFIRI between patients with UGT1A1*1/*1 genotype and those with UGT1A1*1/*6 or *1/*28 genotype. Our results suggest that patients with the latter genotypes can receive FOLFIRI at the same dose of irinotecan as those with the UGT1A1*1/*1 genotype receive.